271 related articles for article (PubMed ID: 33054823)
21. Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus.
Giangreco D; Devilliers H; Annapureddy N; Block JA; Jolly M
Lupus; 2015 Dec; 24(14):1486-91. PubMed ID: 26162686
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers JO; Genre F; Hiepe F; Gerosa M; Kovács L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; ; Alarcón-Riquelme ME; Beretta L
Ann Rheum Dis; 2024 Jun; 83(7):889-900. PubMed ID: 38373843
[TBL] [Abstract][Full Text] [Related]
23. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Yu D; Karyekar CS; Sing Lau C; Monk JA; Nikpour M; Hoi A; Morand EF;
Lancet Rheumatol; 2022 Dec; 4(12):e822-e830. PubMed ID: 38261390
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
Golder V; Kandane-Rathnayake R; Huq M; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337
[TBL] [Abstract][Full Text] [Related]
25. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
[TBL] [Abstract][Full Text] [Related]
26. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
[TBL] [Abstract][Full Text] [Related]
27. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity.
Wolfe F; Petri M; Alarcón GS; Goldman J; Chakravarty EF; Katz RS; Karlson EW
J Rheumatol; 2009 Jan; 36(1):82-8. PubMed ID: 19004039
[TBL] [Abstract][Full Text] [Related]
28. Remission in SLE-do DORIS criteria match the treating physician's judgment? A cross-sectional study to assess reasons for discordance.
Mucke J; Düsing C; Klose N; Schneider M; Chehab G
Rheumatology (Oxford); 2021 Sep; 60(9):4298-4305. PubMed ID: 33493321
[TBL] [Abstract][Full Text] [Related]
29. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS).
Chaigne B; Chizzolini C; Perneger T; Trendelenburg M; Huynh-Do U; Dayer E; Stoll T; von Kempis J; Ribi C;
BMC Immunol; 2017 Mar; 18(1):17. PubMed ID: 28351341
[TBL] [Abstract][Full Text] [Related]
30. Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity.
Svenungsson E; Gunnarsson I; Illescas-Bäckelin V; Trysberg E; Jönsen A; Leonard D; Sjöwall C; Pettersson S
Lupus Sci Med; 2021 May; 8(1):. PubMed ID: 33972457
[TBL] [Abstract][Full Text] [Related]
31. 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.
Kandane-Rathnayake R; Louthrenoo W; Hoi A; Luo SF; Wu YJ; Chen YH; Cho J; Lateef A; Hamijoyo L; Navarra SV; Zamora L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Hao Y; Zhang Z; Kikuchi J; Takeuchi T; Basnayake BMDB; Chan M; Ng KPL; Tugnet N; Kumar S; Oon S; Goldblatt F; O'Neill S; Gibson KA; Ohkubo N; Tanaka Y; Bae SC; Lau CS; Nikpour M; Golder V; Morand EF;
Arthritis Res Ther; 2022 Mar; 24(1):70. PubMed ID: 35287720
[TBL] [Abstract][Full Text] [Related]
32. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
[TBL] [Abstract][Full Text] [Related]
33. External Validation of the Lupus Impact Tracker in a Southeastern US Longitudinal Cohort With Systemic Lupus Erythematosus.
Brandt JE; Drenkard C; Kan H; Bao G; Dunlop-Thomas C; Pobiner B; Chang DJ; Jolly M; Lim SS
Arthritis Care Res (Hoboken); 2017 Jun; 69(6):842-848. PubMed ID: 27564570
[TBL] [Abstract][Full Text] [Related]
34. LLDAS is an attainable treat-to-target goal in childhood-onset SLE.
Wahadat MJ; van den Berg L; Timmermans D; van Rijswijk K; van Dijk-Hummelman A; Bakx S; Verkaaik M; Versnel MA; Kamphuis S
Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34969874
[TBL] [Abstract][Full Text] [Related]
35. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.
Tani C; Vagelli R; Stagnaro C; Carli L; Mosca M
Lupus Sci Med; 2018; 5(1):e000234. PubMed ID: 29531772
[TBL] [Abstract][Full Text] [Related]
36. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus.
Samões B; Zen M; Abelha-Aleixo J; Gatto M; Doria A
Autoimmun Rev; 2022 Oct; 21(10):103165. PubMed ID: 35931316
[TBL] [Abstract][Full Text] [Related]
37. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus.
Yeo AL; Koelmeyer R; Kandane-Rathnayake R; Golder V; Hoi A; Huq M; Hammond E; Nab H; Nikpour M; Morand EF
Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076
[TBL] [Abstract][Full Text] [Related]
38. Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study.
Miyawaki Y; Shimizu S; Ogawa Y; Sada KE; Katayama Y; Asano Y; Hayashi K; Yamamura Y; Hiramatsu-Asano S; Ohashi K; Morishita M; Watanabe H; Takano-Narazaki M; Matsumoto Y; Yajima N; Yoshimi R; Shimojima Y; Ohno S; Kajiyama H; Ichinose K; Sato S; Fujiwara M; Yamazaki H; Yamamoto Y; Wada J; Fukuhara S
Arthritis Res Ther; 2021 Mar; 23(1):79. PubMed ID: 33691746
[TBL] [Abstract][Full Text] [Related]
39. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Type 2 SLE symptoms in patients with a range of lupus nephritis activity.
Rogers JL; Clowse MEB; Pisetsky DS; Criscione-Schreiber LG; Sun K; Sadun RE; Maheswaranathan M; Burshell DR; Doss J; Eudy AM
Clin Rheumatol; 2024 Apr; 43(4):1319-1326. PubMed ID: 38409491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
